AR067110A1 - COMBINED PHARMACEUTICAL COMPOSITION - Google Patents

COMBINED PHARMACEUTICAL COMPOSITION

Info

Publication number
AR067110A1
AR067110A1 ARP080102666A ARP080102666A AR067110A1 AR 067110 A1 AR067110 A1 AR 067110A1 AR P080102666 A ARP080102666 A AR P080102666A AR P080102666 A ARP080102666 A AR P080102666A AR 067110 A1 AR067110 A1 AR 067110A1
Authority
AR
Argentina
Prior art keywords
cover
pharmaceutical composition
polymer
plasticizer
antioxidant
Prior art date
Application number
ARP080102666A
Other languages
Spanish (es)
Inventor
Portocarrero Jose Eduardo Santillana
Paniagua Angelica Arzola
Ramirez Martha Keyla Corona
Original Assignee
Senosiain S A De C V Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40228222&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR067110(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Senosiain S A De C V Lab filed Critical Senosiain S A De C V Lab
Publication of AR067110A1 publication Critical patent/AR067110A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composicion farmacéutica en cápsulas con microesferas recubiertas que comprende la combinacion de besilato de amlodipino y pravastatina sodica y sus sales farmacéuticamente aceptables, adicionalmente vehículos o excipientes farmacéuticamente aceptables; así como a un proceso para la fabricacion de la composicion y al uso de dicha combinacion para la preparacion de un medicamento con actividad terapéutica sinérgica indicado en el tratamiento de padecimientos cardiovasculares del tipo de hipertension arterial y dislipidemia y su comorbilidad. Reivindicacion 3: La composicion .farmacéutica de la reivindicacion 2 caracterizada: porque las microesferas recubiertas comprenden: Nucleos inertes; a) Cubierta uno, que incluye al principio activo uno, al menos un antioxidante, al menos un plastificante, al menos un amortiguador, y al menos un polímero adhesivo ligante aglutinante; b) Cubierta aislante que incluye, al menos un polímero en solucion acuosa; c) Cubierta que incluye al principio activo dos, al menos un antioxidante, al menos un plastificante, al menos un amortiguador, y al menos un polímero adhesivo ligante aglutinante; y d) Cubierta protectora de recubrimiento, que incluye al menos un polímero de recubrimiento y al menos un excipiente.Pharmaceutical composition in capsules with coated microspheres comprising the combination of amlodipine besylate and sodium pravastatin and its pharmaceutically acceptable salts, additionally pharmaceutically acceptable carriers or excipients; as well as a process for the manufacture of the composition and the use of said combination for the preparation of a medication with synergistic therapeutic activity indicated in the treatment of cardiovascular diseases of the type of arterial hypertension and dyslipidemia and their comorbidity. Claim 3: The pharmaceutical composition of claim 2 characterized in that the coated microspheres comprise: inert nuclei; a) Cover one, which includes the active ingredient one, at least one antioxidant, at least one plasticizer, at least one buffer, and at least one binding binder adhesive polymer; b) Insulating cover that includes at least one polymer in aqueous solution; c) Cover which includes at the active principle two, at least one antioxidant, at least one plasticizer, at least one buffer, and at least one binding binder adhesive polymer; and d) Protective coating cover, which includes at least one coating polymer and at least one excipient.

ARP080102666A 2007-07-11 2008-06-20 COMBINED PHARMACEUTICAL COMPOSITION AR067110A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2007008440A MX2007008440A (en) 2007-07-11 2007-07-11 Combined pharmaceutical composition.

Publications (1)

Publication Number Publication Date
AR067110A1 true AR067110A1 (en) 2009-09-30

Family

ID=40228222

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080102666A AR067110A1 (en) 2007-07-11 2008-06-20 COMBINED PHARMACEUTICAL COMPOSITION

Country Status (7)

Country Link
AR (1) AR067110A1 (en)
CL (1) CL2008001895A1 (en)
MX (1) MX2007008440A (en)
PA (1) PA8785701A1 (en)
PE (1) PE20090439A1 (en)
UY (1) UY31153A1 (en)
WO (1) WO2009007808A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101804055B (en) * 2010-04-27 2012-01-25 施慧达药业集团(吉林)有限公司 Compound medicinal preparation
MX351059B (en) * 2012-08-17 2017-09-29 Laboratorios Senosiain S A De C V Star Oral pharmaceutical composition in the form of microspheres and preparation method.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0003103A3 (en) * 1997-08-29 2002-03-28 Pfizer Prod Inc Combination therapy comprising amlodipine and a statin compound
AU2001284413A1 (en) * 2000-08-30 2002-03-13 Sankyo Company Limited Medicinal compositions for preventing or treating heart failure

Also Published As

Publication number Publication date
PA8785701A1 (en) 2009-04-23
WO2009007808A4 (en) 2009-03-05
CL2008001895A1 (en) 2008-08-22
PE20090439A1 (en) 2009-05-24
UY31153A1 (en) 2009-03-02
WO2009007808A1 (en) 2009-01-15
MX2007008440A (en) 2009-02-18

Similar Documents

Publication Publication Date Title
BR112018015273A2 (en) benzimidazole derivatives as ror-gamma modulators
ECSP12011838A (en) CHROMENONE DERIVATIVES WITH ANTI-TUMORAL ACTIVITY
CL2011003266A1 (en) Compounds derived from imidazolidin-2-one, with inhibitory activity of 17alpha-hydroxylase / lyase-c17,20; pharmaceutical composition comprising them; and use in the treatment of inflammation or cancer, among others.
CR20170563A (en) BENZOXACEPIN OXAZOLIDINONE COMPOUNDS AND METHODS OF USE.
DOP2010000011A (en) DERIVATIVES OF PIRIMIDINE TRISUSTITUIDA FOR THE TREATMENT OF PROLIFERATIVE DISEASES
DK2324008T3 (en) Diarylpyrazole as protein kinase inhibitors
GT200600096A (en) PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT
BR112015018087A8 (en) compound, pharmaceutical composition and use
CO6251364A2 (en) DERIVATIVES OF MORFOLINO PIRIMIDINA USED IN DISEASES RELATED TO MTOR QUINASA AND / OR P13K
CL2013001339A1 (en) Condensed heterocyclic derivative compounds, with antiviral activity; pharmaceutical composition that includes them; and its use for the prevention or treatment of HIV infection.
ECSP109934A (en) COMPOUND - 946
BR112015030315A2 (en) 4-alkynylimidazole derivative and medicament comprising the same as active ingredient
UY33183A (en) INHIBITING COMPOUNDS OF VIRUS FLAVIVIRIDAE, PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM AND ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT
CL2015002608A1 (en) Amino-pyrazole compound and related medicinal uses.
CO6491060A2 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITARY DISEASES
BR112015027114A2 (en) novel compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same
BR112015011179A8 (en) stable aqueous pharmaceutical compositions comprising human insulin or an analogue or derivative thereof, their use and processes for their preparation
BRPI0517792A (en) macrolones - amino substituted quinolones
BR112014010563A2 (en) aminopyrimidine kinase inhibitors
CU20140037A7 (en) DERIVATIVES OF ESTRA- 1,3,5 (10), 16- TETRAEN- 3- CARBOXIMIDE, PROCEDURES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS THAT CONTAIN THEM, AS WELL AS THEIR USE FOR THE PREPARATION OF MEDICINES
CL2011000798A1 (en) Use of dabigatran etexilate or a salt thereof to prepare a useful medication for the prevention of stroke in patients suffering from atrial fibrillation.
BR112014018795A2 (en) 1h-pyrrolo [2,3-b] pyridine derivatives and their use as kinase inhibitors
CR20180184A (en) HETEROARILO COMPOUNDS AND ITS USE AS THERAPEUTIC DRUGS
CL2007000781A1 (en) NANOPARTICLES THAT INCLUDE A THYROSINE KINASE INHIBITOR RECEIVING THE GROWTH FACTOR DERIVED FROM PLATES; PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF VASCULAR DISEASES, SUCH AS RESTENOSIS
CR20110704A (en) COMPOSITIONS OF FIXED DOSAGE SOLID PHARMACEUTICALS THAT INCLUDE IRBESARTAN AND AMYLODIPINE, ITS PREPARATION AND THERAPEUTIC APPLICATION

Legal Events

Date Code Title Description
FB Suspension of granting procedure